高级检索
当前位置: 首页 > 详情页

Effects of salvianolic acid B on L-type calcium channels and myocardial contractility in isolated rat ventricular myocytes and hERG K+ channels expressed in HEK293 cells

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Hebei University of Chinese Medicine, No. 3, Xingyuan Road, Shijiazhuang, Hebei 050200, China [2]The Fourth Hospital of Hebei Medical University, No. 12, Jiankang Road, Shijiazhuang, Hebei 050011, China [3]Hebei Key Laboratory of Integrative Medicine on Liver-Kidney Patterns, Shijiazhuang, Hebei 050200, China
出处:
ISSN:

关键词: Salvianolic acid B L-type calcium current Rapidly activating delayed rectifier potassium current Myocardial contractility Calcium overload Drug-induced long QT syndrome

摘要:
Salvianolic acid B (Sal B), one of the chief water-soluble constituents in Radix Salviae Milthiorrhizae, has often been reported to possess considerable cardiovascular regulatory effects. However, the underlying biochemical and cellular mechanisms of its cardioprotection remain unclear. This study was designed to evaluate the role of Sal B regulation in L-type Ca2+ channel currents (I-Ca,I-L) and cell contractility in rat cardiomyocytes and hERG K+ channels expressed in HEK293 cells with the patch-clamp and Ca2+ imaging techniques to clarify its underlying cardioprotective mechanisms. Exposure to Sal B blocked I-Ca,I-L with IC50 of 2.07 x 10(-5) M, shifted the curves of current and voltage upwards, shifted the curves of activation and inactivation to the left, and significantly inhibited the amplitude of the cell shortening, but the regulatory effects of Sal B on the expressed rapidly activating delayed rectifier potassium current (I-Kr) did not reach a significant level. These results indicate that the cardioprotective mechanisms of Sal B may be related to the attenuation of calcium overload by directly inhibiting I-Ca,I-L and consequently decreasing myocardial contractility without causing drug-induced long QT syndrome (LQTS).

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2017]版:
大类 | 3 区 医学
小类 | 3 区 药学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 药学
JCR分区:
出版当年[2017]版:
Q3 PHARMACOLOGY & PHARMACY
最新[2024]版:
Q2 PHARMACOLOGY & PHARMACY

影响因子: 最新[2024版] 最新五年平均 出版当年[2017版] 出版当年五年平均 出版前一年[2016版] 出版后一年[2018版]

第一作者:
第一作者机构: [1]Hebei University of Chinese Medicine, No. 3, Xingyuan Road, Shijiazhuang, Hebei 050200, China
通讯作者:
通讯机构: [1]Hebei University of Chinese Medicine, No. 3, Xingyuan Road, Shijiazhuang, Hebei 050200, China [3]Hebei Key Laboratory of Integrative Medicine on Liver-Kidney Patterns, Shijiazhuang, Hebei 050200, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:42313 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号